MuSK myasthenia gravis monoclonal antibodies
Valency dictates pathogenicity
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 3, 2018
- Accepted in final form January 14, 2019
- First Published February 21, 2019.
Author Disclosures
- Maartje G. Huijbers, PhD,
- Dana L. Vergoossen, MSc,
- Yvonne E. Fillié-Grijpma,
- Inge E. van Es, BASc,
- Marvyn T. Koning, BSc,
- Linda M. Slot, MSc,
- Hendrik Veelken, MD, PhD,
- Jaap J. Plomp, PhD,
- Silvère M. van der Maarel, PhD* and
- Jan J. Verschuuren, MD, PhD*
- Maartje G. Huijbers, PhD,
NONE
NONE
NONE
NONE
I am co-inventor on several patent applications related to MuSK MG pathogenesis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dana L. Vergoossen, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yvonne E. Fillié-Grijpma,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Inge E. van Es, BASc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marvyn T. Koning, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Professor Steenhuis Fund
NONE
NONE
NONE
NONE
NONE
NONE
- Linda M. Slot, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hendrik Veelken, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jaap J. Plomp, PhD,
NONE
NONE
NONE
NONE
Two patents pending on the pathomechanisms of MuSK MG antibodies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Silvère M. van der Maarel, PhD* and
Prinses Beatrix Spierfonds, non-profit CORT, non-profit MRC Centre for Neuromuscular Diseases, non-profit Dutch CAA foundation, non-profit Spierziekten Centrum Nederland, non-profit
NONE
NONE
Neuromuscular Disorders, editorial board, ongoing
SMvdM is coinventor on several patent applications relatedto FSHD and to MuSK MG
NONE
GenomeScan, non-executive board member
Fulcrum Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan J. Verschuuren, MD, PhD*
Myasthenia Foundation of America (MGFA) medical/scientific advisory board
NONE
NONE
Journal of Neuromuscular Diseases, member editorial board, 2014-now
Patents on MuSK myasthenia gravis
NONE
NONE
The Neurology department of the LUMC has received fees from Alexion, Argen-X, and Rapharma because of consultancies
NONE
NONE
NONE
NONE
NONE
NONE
Princes Beatrix Spierfonds, grant for MG research, Prinicpal investigator.
NONE
NONE
Development of MuSK diagnostic antibody test for TECAN/IBL. Yearly payments to the LUMC
NONE
NONE
NONE
- From the Department of Neurology (M.G.H., Y.E.F.-G., I.E.v.E., J.J.P., J.J.V.), Department of Human Genetics (M.G.H., D.L.V., Y.F.-G., I.E.v.E., S.M.v.d.M.), Department of Hematology (M.T.K., H.V.), and Department of Rheumatology (L.M.S.), Leiden University Medical Center, The Netherlands.
- Correspondence
Dr. Huijbers M.G.M.Huijbers{at}lumc.nl
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibodySaif Huda, Michelangelo Cao, Anna De Rosa et al.Neurology: Neuroimmunology & Neuroinflammation, December 12, 2019 -
What's Happening
What's happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, September 30, 2019 -
Editorial
Treating muscle-specific kinase myasthenia gravis from the inside outMaartje G. Huijbers, Jan J.G.M. Verschuuren et al.Neurology: Neuroimmunology & Neuroinflammation, December 12, 2019 -
Editor's Corner
A surprise with MuSK antibodiesJosep Dalmau et al.Neurology: Neuroimmunology & Neuroinflammation, May 02, 2019